Roche Diagnostics Gmbh

Hans Koll

Anne Stern

Michael Brandt

Konrad Honold

Johannes Auer

Reinhard Franze

Ulrich Pessara

Gerhard Winter

Josef Burg

Thomas Kissel

Karl-Heinz Sellinger

Anton Haselbeck

Michael Morlock

The invention concerns new EPO compositions with high specific activity which are characterized by a high proportion of N-acetyl-lactosamine units or/and tetraantennary branches in the carbohydrate structure. In addition the invention concerns a process for producing such EPO products.

Erythropoietin with high specific activity

The invention concerns human cells which, due to an activation of the endogenous human EPO gene, are able to produce EPO in an adequate quantity and purity to enable a cost-effective production of human EPO as a pharmaceutical preparation. Furthermore the invention concerns a process for the production of such human EPO-producing cells, DNA constructs for the activation of the endogenous EPO gene in human cells as well as a process for the large-scale production of EPO in human cells.

Methods for identifying human cell lines useful for endogenous gene activation, isolated human cell lines identified thereby, and uses thereof

The invention relates to human cells which are capable, on the basis of an activation of the endogenous human EPO gene, of producing EPO in a sufficient amount and purity to make possible a cost-effective production of human EPO as a pharmaceutical preparation. The invention furthermore relates to a method for the preparation of such human EPO-producing cells, DNA constructs for the activation of the endogenous EPO in human cells, and a method for the large technical production of EPO in human cells.

Preparation of erythropoietin by endogenous gene activation

Methods for identifying human cell lines useful for endogenous gene activation isolated human cell lines identified thereby, and uses thereof

Methods for identifying human cell lines useful for endogenous gene activation, isolated human lines identified thereby, and uses thereof

The invention relates to human cells which are capable, on the basis of an activation of the endogenous human EPO gene, of producing EPO in a sufficient amount and purity to make possible a cost-effective production of human EPO as a pharmaceutical preparation. The invention furthermore relates to a method for the preparation of such human EPO-producing cells, DNA constructs for the activation of the endogenous EPO inhuman cells, and a method for the large technical production of EPO in human cells.

Production of erythropoietin by endogenous gene activation

The invention concerns parenteral pharmaceutical forms of administration containing polypeptide in the form of microparticles and a process for the production thereof. The microparticles according to the invention contain as a biodegradable polymer an ABA triblock copolymer the A block of which is a copolymer of lactic and glycolic acid and the B block of which represents a polyethylene glycol chain, together with additives that are selected from the group comprising serum proteins, polyamino acids, cyclodextrins, cyclodextrin derivatives, saccharides, amino sugars, amino acids, detergents or carboxylic acids as well as mixtures of these additives. The microparticles according to the invention continuously release the polypeptide over a relatively long time period even when the amounts of polypeptide they include are small or susceptible to aggregation.

Polypeptide-containing pharmaceutical forms of administration in the form of microparticles and method for the preparation thereof

Growing community of inventors

Weilheim, Germany

Hans Koll